- Home
- BIRD vs MIST Comparison
BIRD vs MIST Comparison
Compare BIRD & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- MIST
- Stock Information
- Founded
- BIRD 2015
- MIST 2003
- Country
- BIRD United States
- MIST Canada
- Employees
- BIRD N/A
- MIST N/A
- Industry
- BIRD Apparel
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- MIST Health Care
- Exchange
- BIRD Nasdaq
- MIST Nasdaq
- Market Cap
- BIRD 87.0M
- MIST 81.5M
- IPO Year
- BIRD 2021
- MIST N/A
- Fundamental
- Price
- BIRD $8.39
- MIST $1.80
- Analyst Decision
- BIRD Hold
- MIST Strong Buy
- Analyst Count
- BIRD 4
- MIST 3
- Target Price
- BIRD $21.50
- MIST $13.00
- AVG Volume (30 Days)
- BIRD 91.5K
- MIST 510.8K
- Earning Date
- BIRD 11-06-2024
- MIST 11-12-2024
- Dividend Yield
- BIRD N/A
- MIST N/A
- EPS Growth
- BIRD N/A
- MIST N/A
- EPS
- BIRD N/A
- MIST N/A
- Revenue
- BIRD $205,895,000.00
- MIST N/A
- Revenue This Year
- BIRD N/A
- MIST N/A
- Revenue Next Year
- BIRD N/A
- MIST N/A
- P/E Ratio
- BIRD N/A
- MIST N/A
- Revenue Growth
- BIRD N/A
- MIST N/A
- 52 Week Low
- BIRD $7.65
- MIST $1.12
- 52 Week High
- BIRD $29.00
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- BIRD 32.04
- MIST 68.42
- Support Level
- BIRD $7.65
- MIST $1.75
- Resistance Level
- BIRD $8.59
- MIST $2.09
- Average True Range (ATR)
- BIRD 0.72
- MIST 0.15
- MACD
- BIRD -0.25
- MIST 0.04
- Stochastic Oscillator
- BIRD 13.53
- MIST 62.86
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).